TSX Venture: QPT
EDMONTON, Jan. 22, 2013 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT)
("Quest" or the "Company"), a pharmaceutical company developing and
commercializing products for the treatment of cancer, announces that it
has achieved 50% accrual having enrolled the 40th patient in its ongoing 80 patient Phase II Oregovomab front-line
chemo-immunotherapy clinical trial in Italy and the U.S.
The objective of this study is to confirm that optimally dosed
oregovomab in combination with standard front-line chemotherapy for
advanced ovarian cancer will generate an improved immune and clinical
response, as seen in preliminary phase II studies, and permit the best
design of a definitive phase III program to follow. Currently, there
are 8 clinical trial centers in Italy enrolling patients, with
Professor Roberto Angioli at Policlinico Universitario Campus
Bio-Medico Di Roma acting as the study chair. The Company is adding
three additional centers in the U.S., to the two active U.S. sites,
through the COGI (Cooperative Ovarian Cancer Group for Immunotherapy)
clinical trials group, under the leadership of Professor Jonathan Berek
at the Stanford Women's Cancer Center, Stanford Cancer Institute.
"We are excited to reach the mid-point in patient enrollment for this
pivotal 80 patient clinical trial", said Madi R. Madiyalakan, Ph.D.,
Chief Executive Officer for Quest. "With 13 centers currently
participating in the trial, we are hopeful that we will achieve full
patient enrollment within this year. This program not only is
evaluating the latest concepts of combination chemo-immunotherapy for
ovarian cancer, but is also providing critical data to facilitate the
pending clinical development of additional cancer antibody
immunotherapeutics within our technology pipeline."
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based biotechnology company
committed to the development and commercialization of oncology product
candidates for the treatment of cancer by combining immunotherapeutic
antibodies with chemotherapy, photodynamic therapy or immunoadjuvants.
Quest's technology platform includes a series of monoclonal antibodies
that target several cancer markers such as CA125, MUC1, PSA, CA19.9 and
TAG72; and proprietary photosensitizers. Quest has body of clinical
experience and a new appreciation of the obstacles and potential of
combinatorial immunotherapeutic approaches to cancer. Quest believes
that combinatorial immunotherapy, which exploits the immune modulating
effects of selected cytotoxic agents normally used in standard
chemotherapy regimens along with specific immune stimulants will lead
to important commercial applications of this immunology platform in the
treatment of cancer.
The most advanced of these product candidates is oregovomab, an
anti-CA125 antibody in combination with front-line chemotherapy for the
treatment of advanced ovarian cancer which is currently undergoing a
phase II clinical trial in 13 centers in Italy and the U.S. The
Company's MUC1 antibody program that has already undergone a phase I
clinical trial has the potential to permit tumor specific immunization
to a broad range of additional cancers, including colon, non small cell
lung, breast and pancreas. Quest is also conducting a phase I clinical
trial for the treatment of prostate cancer, with its photosensitizer,
About The Cooperative Ovarian Cancer Group for Immunotherapy (COGI)
The Cooperative Ovarian Cancer Group for Immunotherapy (COGI), based at
Stanford University, is a consortium of ovarian cancer researchers from
22 leading academic medical centers throughout the United States and
United Kingdom, including Stanford University, Harvard University,
Memorial Sloan Kettering Cancer Center, University of Pennsylvania, and
the University of Washington. This group was formed in 2004 to focus on
the development of vaccines and innovative immunotherapies for ovarian
cancer. COGI is led by the group's principal investigator, Dr. Jonathan Berek, Professor and Chair, Stanford Women's Cancer Center, Stanford Cancer
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Quest PharmaTech Inc.
For further information:
Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: email@example.com, Internet: www.questpharmatech.com.